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Background:  Although  drug-eluting  stents  (DES)  reduce  restenosis,  the  best  strategy  for DES  implantation
in  small  vessels  has  not  been  established.
Purpose:  We  investigated  the  clinical  usefulness  of  low-pressure  implantation  of  a 2.5-mm  DES  for  small
vessels  less  than  2.5  mm  in  diameter.
Methods:  In 118  patients,  a 2.5-mm  DES  was  implanted  for small  vessels  less  than  2.5 mm  in  diameter
between  2007  and  2009  in  our  hospital.  The  patients  were  divided  into  two  groups  by  initial  deployment
pressure:  low-pressure  (LP; n  = 46) and  nominal-pressure  (NP;  n  =  72).
Results:  Patients  with  impaired  glucose  tolerance  were  more  frequent  (p =  0.02)  and  the target  vessel
diameter  was  signiﬁcantly  smaller  (p  = 0.01)  in  the  LP  group  than  in  the  NP group.  A smaller  mini-
mum  lumen  diameter  (MLD)  was  obtained  (LP: 2.22 ±  0.27  mm  vs.  NP:  2.34  ± 0.26  mm,  p  = 0.02)  after
DES  implantation  with  a smaller  balloon-to-artery  ratio  (p  = 0.03)  in  the  LP  group.  However,  at  mid-term
follow-up  (7.7 ± 3.9 months),  MLD  (p = 0.55) and  the  binary  restenosis  rate  (LP:  2.6%  vs. NP: 11.1%,  p =  0.12)
were  not  signiﬁcantly  different  between  the  LP  and NP  groups.  Furthermore,  by  Kaplan–Meier  analysis,
the  incidence  of  major  adverse  cardiac  events  was  not  different  between  the  groups  during  the  long-term
follow-up  (32.4  ± 8.6 months).
Conclusion:  The  present  study  indicates  that low-pressure  implantation  of  2.5-mm  DES for  very small
ith  re
©  2vessels  may  be  feasible  w
ntroduction
The incidence of small coronary vessel disease has increased
n parallel with a higher prevalence of diabetes mellitus (DM),
nd represents a challenge for myocardial revascularization. Small
oronary reference vessel diameter predicts adverse clinical and
ngiographic outcomes following coronary stent deployment
1–3]. This may  be due to the disproportionately greater amount
f neointimal tissue relative to the vessel caliber [4]. It has been
hown that drug-eluting stents (DES) reduce angiographic resteno-
is and improve the rate of event-free survival in patients who
ave coronary artery diseases and are at low risk of restenosis
5,6]. Recent reports have also shown the efﬁcacy of DES under
ore challenging conditions such as long and complex lesions,
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and post hoc analyses of trial subpopulations suggest that DES
may  also be effective for preventing restenosis in small vessels
[7,8]. More recently, the use of DES in vessels ≤2.75 mm has been
demonstrated to reduce angiographic late lumen loss and binary
restenosis as well as target lesion revascularization when compared
with bare-metal stents (BMS) [9–12]. However, DES  implanta-
tion for small vessel disease remains a signiﬁcant challenge. In
particular, when the vessel size is smaller than the stent size, it
may  be critical to deploy the stent under lower pressure to pre-
vent intra-procedural complications. However, since there have
been no detailed descriptions of stent-deployment pressures in
the previous studies, it has been unclear whether low-pressure
(below nominal) DES implantation is feasible for very small coro-
nary arteries. In the present study, therefore, we  investigated the
DES-implantation strategy for small vessel disease in terms of
stent-deployment pressure. We analyzed clinical outcomes includ-
ing angiographic and procedural data in 118 consecutive patients
with 2.5-mm DES implantation for small vessels less than 2.5 mm
in diameter, and clariﬁed the safety and efﬁcacy of low-pressure
implantation.
llege of Cardiology.
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patients taking aspirin. Patients in the LP group had IGT  more
frequently than those in the NP group (23.9% in LP group vs. 8.3%
in NP group, p = 0.019) (Table 1).
119: Eligible patients
72:
Nominal pressure (NP) group
46:
Low pressure (LP) group
60: Target vessel diameter  ≥ 2.5 mm
1: Stent deployment pressure was unknown
179:  Patients receiving implantation of 2.5 mmdiameter DES
Fig. 1. Patient enrollment. The analyses were based on the ﬁrst recorded per-
cutaneous coronary intervention procedure when the patient underwent several
implantations of drug-eluting stent (DES) of 2.5 mm diameter.
Table 1
Patient characteristics.
NP group (n = 72) LP group (n = 46) p-Value
Male (%) 57 (79.2) 36 (78.3) 0.906
Age  (years) 69.3 ± 9.0 70.8 ± 7.6 0.310
BMI  23.8 ± 3.0 23.6 ± 3.2 0.838
HLP  (%) 57 (79.2) 38 (82.6) 0.645
HT  (%) 51 (70.8) 32 (69.6) 0.883
Smoking (%) 25 (34.7) 20 (43.5) 0.340
DM  (%) 34 (47.2) 25 (54.4) 0.450
IGT  (%) 6 (8.3) 11 (23.9) 0.019
OMI (%) 36 (50.0) 18 (39.1) 0.248
Serum creatinine (mg/dL) 1.01 ± 0.81 0.96 ± 0.32 0.670
Medication (admission)
Aspirin (%) 65 (90.3) 46 (100) 0.029
Thienopyridine (%) 63 (87.5) 45 (97.8) 0.050
Ca-blocker (%) 23 (31.9) 18 (39.1) 0.424
Nicorandil (%) 5 (6.9) 8 (17.4) 0.077
-Blocker (%) 40 (55.6) 33 (71.7) 0.078
Nitrate (%) 7 (9.7) 6 (13.0) 0.574
Statin (%) 36 (50.0) 26 (56.5) 0.489
ACEI/ARB (%) 40 (55.6) 21 (45.7) 0.294
Diuretic (%) 16 (22.2) 8 (17.4) 0.525
Diagnosis (admission) 0.493
SAP  (%) 55 (76.4) 38 (82.6)
UAP (%) 17 (23.6) 8 (17.4)T. Suga et al. / Journal of 
ethods
atient population
In the present study, we included consecutive patients who
nderwent percutaneous coronary intervention (PCI) with a DES of
.5-mm diameter between April 2007 and July 2009 in our hospi-
al. Patients with target vessel diameters of 2.5 mm or greater were
xcluded. The eligible patients were divided by initial deployment
ressure into two groups: nominal-pressure (NP) group and low-
ressure (LP) group. The analyses were based on the PCI procedure
t the ﬁrst recorded procedure during the period. The diagnosis
f DM included 75-g oral glucose tolerance test or already taking
ntidiabetic drugs. Impaired glucose tolerance (IGT) was  diagnosed
y 75-g oral glucose tolerance test.
CI procedure and angiographical analysis
PCI was performed with the standard technique and the strat-
gy was selected at the discretion of the individual PCI operator.
he ﬁrst inﬂation pressure of the 2.5-mm DES delivery was deﬁned
s the stent deployment pressure. The NP group consisted of those
atients whose stent deployment pressure was  nominal pressure
r higher. The LP group consisted of those whose deployment pres-
ure was lower than nominal pressure. The nominal pressures used
ere 11 atm for sirolimus-eluting stent (SES, Cypher®, Cordis Cor-
oration, Miami  Lakes, FL, USA) and 9 atm for paclitaxel-eluting
tent (PES, Taxus®, Boston Scientiﬁc, Natick, MA,  USA) as deﬁned by
he respective manufacturers’ packaging. After stent deployment,
dditional balloon inﬂation at the proximal part was performed
hen the reference diameter of the proximal part was  estimated
o be clearly bigger than that of the distal part. In most cases (95.2%
f the patients), inﬂation of the stent balloon with higher pres-
ure (8–20 atm) was performed for it. The number of inﬂations
as dependent on the acute gain of stent ﬁtting and for 21.4% of
he patients inﬂation was performed 2 or 3 times. Intraprocedural
omplications were deﬁned as coronary dissection, rupture, acute
cclusion, slow or no ﬂow, and acute myocardial infarction.
Patients received intracoronary isosorbide dinitrate (1–5 mg)
rior to initial angiograms to achieve maximal vasodilation. Quanti-
ative coronary angiography (QCA) was performed for all qualifying
ngiograms using CAAS II (Pie Medical Imaging, Maastricht, The
etherlands). Measurements included the minimum lumen diam-
ter (MLD) at proximal edge, in-stent, or distal edge of the treated
oronary segment, the reference diameter and the lesion length
efore and after each intervention and at follow-up study.
Angiographic follow-up was recommended in all patients at 9
onths after PCI. Angiographic restenosis was  deﬁned as a ≥50%
iameter stenosis within the target lesion.
linical follow-up
The end point of the survey was the occurrence of intraprocedu-
al complications or major adverse cardiac events (MACE), deﬁned
s (1) death (cardiac and non-cardiac), (2) nonfatal acute myocar-
ial infarction (AMI), or (3) target-lesion revascularization (TLR).
MI during follow-up was diagnosed by cardiologists at the hospi-
al of admission according to standard criteria. TLR was performed
f the lesion had signiﬁcant luminal stenosis (>50% diameter steno-
is) in the presence of angina symptoms and/or proven myocardial
schemia in the target lesion.
tatistical analysisData are expressed as means ± SD for continuous variables
nd as frequencies for categorical variables. Categorical data were
nalyzed with a 2 test and continuous variables were evaluatedlogy 63 (2014) 218–222 219
with a Student t-test. The cumulative incidences of MACE were
estimated according to the Kaplan–Meier method. Differences
between the event-free survival curves for the 2 groups were
compared using a log-rank test. Probability values <0.05 were
considered signiﬁcant. Data were analyzed with JMP  9.0.0 for
Windows (SAS, Cary, NC, USA).
Results
Baseline characteristics
A total of 179 patients underwent PCI with 2.5-mm DES, and
60 patients were excluded because their reference diameter
exceeded 2.5 mm.  In one patient, the initial deployment pressure
was unknown, and the remaining 118 patients were divided into
two groups according to the initial inﬂation pressure: 72 patients
belonged to the NP group and 46 patients to the LP group (Fig. 1).
The mean age of the studied patients was 69.9 ± 8.5 years and
78.8% were men. No signiﬁcant differences were observed in
baseline demographics except for the prevalence of IGT and ofValues are mean ± SD or number (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BMI, body mass index; DM,  diabetes mellitus; HLP, hyperlipidemia; HT, hyperten-
sion; IGT, impaired glucose tolerance; LP, low pressure; NP, nominal pressure; OMI,
old myocardial infarction; SAP, stable angina pectoris; UAP, unstable angina pectoris.
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oronary angiography and PCI
At baseline, the reference vessel diameter (RVD) was  signif-
cantly smaller in the LP group (1.94 ± 0.26 mm in LP group vs.
.04 ± 0.22 mm in NP group, p = 0.017) (Table 2). There were no
ifferences in lesion length and American College of Cardiol-
gy/American Heart Association lesion-type classiﬁcation. Three
atients were treated with PES: two in the NP group and one
n the LP group, and the remainder were treated with SES. The
nitial deployment pressure was 13.2 ± 1.9 atm in the NP group vs.
.0 ± 1.0 atm in the LP group (p < 0.001). The balloon-to-artery ratio
as signiﬁcantly lower in the LP group (p = 0.030), indicating less
rterial injury by LP-stent deployment. Additional dilatation was
erformed more frequently in the LP group (84.8% in the LP group
s. 62.5% in the NP group, p = 0.009), but its maximum pressure
as lower than that in the NP group (p < 0.001). There were no
ifferences in the number of inﬂations and balloon types used.
Two intraprocedural complications occurred in the NP group
coronary dissection and acute occlusion) and one occurred in the
P group (slow-ﬂow phenomenon). The incidence was  not signiﬁ-
antly different between the two groups.
id- and long-term outcomesAngiographical (mid-term) follow-up was performed in 86.4%
f the entire patients, which showed no difference between the
P and LP groups. Complete long-term follow-up was available
n 98.4% of the patients. Fig. 2 shows serial changes of MLD.
able 2
ngiographical ﬁndings and PCI procedure.
NP group
(n = 72)
LP group
(n = 46)
p-Value
(A) Baseline ﬁndings
Reference diameter (mm)  2.04 ± 0.22 1.94 ± 0.26 0.017
%  diameter stenosis (%) 64.3 ± 15.4 65.8 ± 16.1 0.609
Lesion length (mm)  17.1 ± 9.0 16.3 ± 9.5 0.669
Treated coronary vessel 0.538
Left anterior descending (%) 39 (54.2) 20 (43.5)
Left circumﬂex (%) 19 (26.4) 18 (39.1)
Right coronary (%) 12 (16.7) 7 (15.2)
Bypass graft (%) 2 (2.8) 1 (2.2)
ACC/AHA type classiﬁcation 0.078
Type A (%) 4 (5.6) 9 (19.6)
Type B1 (%) 21 (29.2) 8 (17.4)
Type B2 (%) 17 (23.6) 12 (26.1)
Type C (%) 30 (41.7) 17 (37.0)
Calciﬁcation (%) 28 (38.9) 16 (34.8) 0.653
Eccentric lesion (%) 26 (36.1) 18 (39.1) 0.741
Chronic total occlusion (%) 6 (8.3) 3 (6.5) 0.718
Number of diseased vessels 1.97 ± 0.75 2.07 ± 0.83 0.529
(B)  PCI procedure
IVUS use (%) 65 (91.5) 43 (93.5) 0.702
Stent length (mm) 19.8 ± 6.1 21.1 ± 6.8 0.306
Balloon-to-artery ratio 1.20 ± 0.16 1.27 ± 0.16 0.030
Initial deployment pressure
(atm)
13.2 ± 1.9 9.0 ± 1.2 <0.001
Additional dilatation (%) 45 (62.5) 39 (84.8) 0.009
Additional dilatation pressure
(atm)
15.7 ± 2.5 13.6 ± 2.8 <0.001
Intraprocedural complications
(%)
2  (2.8) 1 (2.2) 0.853
(C)  Follow-up ﬁndings at mid-term
Follow-up period (month) 8.6 ± 4.3 7.7 ± 3.1 0.225
DAPT continuation (%) 62 (98.4) 37 (100) 0.4412
Reference diameter (mm)  2.32 ± 0.25 2.15 ± 0.26 0.001
Late lumen loss (mm)  0.29 ± 0.49 0.26 ± 0.32 0.701
%  diameter stenosis (%) 11.8 ± 20.6 7.1 ± 15.5 0.227
Binary restenosis (%) 7 (11.1) 1 (2.2) 0.119
alues are mean ± SD or number (%). DAPT, dual antiplatelet therapy; ACC/AHA,
merican College of Cardiology/American Heart Association; IVUS, intravascular
ltrasound; LP, low pressure; NP, nominal pressure.logy 63 (2014) 218–222
Signiﬁcantly smaller MLD  was obtained after stent implantation in
the LP group (2.22 ± 0.27 mm in the LP group vs. 2.34 ± 0.26 mm in
the NP group, p = 0.020). However, at mid-term follow-up (median,
7.7 ± 3.9 months) the difference disappeared (1.99 ± 0.39 mm in
the LP group vs. 2.05 ± 0.54 mm  in the NP group, p = 0.550). As
shown in Table 2C, the late lumen loss and the binary restenosis
rate were not signiﬁcantly different between the two  groups. Fur-
thermore, by Kaplan–Meier analysis, the incidence of MACE was
not different between the LP and NP groups during the long-term
follow-up at a median of 32.4 ± 8.6 months (Fig. 3, p = 0.843). One
case of cardiac death was  observed. In addition, 6 cases of TLR
were observed during the follow-up period (3 cases in each group).
There were no cases of nonfatal AMI. There was  no MACE in three
patients treated with PES.
Discussion
The main ﬁndings of the present study are: (1) low-pressure
implantation of the 2.5-mm DES for small vessels less than 2.5 mm
in diameter was safe and associated with low rates of intra-
procedural complication; (2) MLD  and the incidence of in-stent
binary restenosis in the LP group were not different from those in
the NP group at mid-term follow-up; (3) there was no increase in
MACE in LP group patients at long-term follow-up. Thus, although
the acute gain in the LP group was  signiﬁcantly less, the clinical
outcomes were equivalent to those in the NP group.
Smaller vessel diameter is a well-recognized predictor of in-
stent restenosis. BMS  has been demonstrated to be superior to
balloon angioplasty in preventing restenosis in large coronary
arteries, but conﬂicting results have been reported for its efﬁcacy
in small vessels [13–16]. More recently, Ardissino et al. reported
Fig. 2. Changes in minimum lumen diameter before and after implantation of drug-
eluting stent, and at follow-up examination. NP, nominal pressure; LP, low pressure.
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Fig. 3. Kaplan–Meier estimates of the probability of major adverse cardiac events
(MACE) in the patients grouped by initial deployment pressure. NP, nominal pres-
sure (solid line); LP, low pressure (dotted line).
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hat the use of SES for small arteries with a diameter of 2.75 mm
r less reduced the restenosis in a randomized trial between SES
nd BMS  [17]. In their study presenting a mean RVD of 2.20 mm,
he patients with DM and type C lesions represented 24.9% and
.3%, respectively. The present study showed a smaller mean RVD
2.14 ± 0.21 mm),  and included more patients with DM (50.0%) and
ype C lesions (34.7%). This may  suggest that smaller vessels are
ore frequently associated with DM and complex lesions, and may
ead to poor prognosis. However, the restenosis rate in our study
ohort (7.1%) was similar to theirs (9.8%), suggesting the efﬁcacy
f 2.5-mm DES implantation into smaller vessels. Recently, Fuji-
oto et al. reported that 2.5-mm SES implantation for small vessels
as safe and provided good long-term (1800 days) outcomes when
ompared to that with a diameter of 2.5 mm or more (non-small
essel group) [18]. It is consistent with our present results.
Each device should be used to obtain the largest acute results as
afely as possible if the goal is to minimize the probability of sub-
equent restenosis [19]. The concept that the bigger the stent, the
ower the restenosis rate will be, has been adopted. Obviously, the
ame amount of lumen loss entails many more consequences for
mall vessels than for larger vessels. However, a larger balloon-to-
rtery ratio may  lead to greater vessel wall injury, thereby inducing
ore intimal hyperplasia, more edge dissections, and more coro-
ary ruptures. It is thus difﬁcult to obtain large acute results safely
n small vessels. However, so long as DES implantation into a
mall vessel is performed safely, even if small MLD  is seen after
tent implantation, a good clinical outcome may  be expected. The
resent strategy of low pressure DES implantation for small vessels
ay  thus be reasonable and feasible. Indeed, our results suggest
hat, although the acute gain (MLD after implantation) was signiﬁ-
antly smaller in the LP group, the stents worked well at mid- and
ong-term follow-up in the high-risk patients with smaller vessel
iseases. In addition, taking into consideration the higher preva-
ence of IGT and smaller RVD in the LP group, the restenosis rate of
.1% appears to be reasonable [20].
The SIRIUS 2.25 trial found that the use of 2.25-mm SES was safe
nd provided favorable 6-month clinical outcomes in smaller ves-
els of 2.0–2.5 mm in diameter [21]. Recently, another study (the
PIRIT SV trial) showed that the 2.25-mm XIENCE NanoTM (Abbott,
bbott Park, IL, USA) was effective and safe in the treatment of small
essels with the reference diameter, 2.13 ± 0.23 mm [22]. In both
rials, where the target lesion and patient characteristics includ-
ng RVD, lesion type, and prevalence of DM were better than those
n our study, the restenosis rates were equivalent to that of our
tudy despite the difference in deployed DES diameter. Since the
.25-mm DES has been recently made available in Japan, it is nec-
ssary to compare our LP strategy of 2.5-mm DES with 2.25-mm
ES implantation in terms of clinical outcomes.
This study had several limitations. First, the study population
as relatively small, and any negative ﬁndings could thus be caused
y a low statistical power. However, our study is the ﬁrst to address
he clinical utility of low-pressure DES implantation into small
oronary arteries. Second, the present study was a retrospective,
on-randomized, and single-center study and had several inherent
imitations, including selection and referral biases. In particular,
he PCI strategy was decided by individual PCI operators and low-
ressure implantation was performed when operators believed
hat the procedure could be performed safely based on angiogra-
hic ﬁndings. The present ﬁndings may  not be applicable to all
he small vessels less than 2.5 mm in diameter and the gener-
lizability should be assessed in larger randomized-trial cohorts.
inally, in the LP group, additional balloon dilatation after ini-
ial DES deployment was performed more frequently above the
P. This might have affected the mid- and long-term outcomes.
owever, the pressure was lower than that in the NP group
p < 0.001), and a sub-analysis of only those patients undergoing
[logy 63 (2014) 218–222 221
additional balloon dilatation demonstrated similar results in terms
of clinical outcomes (data not shown).
In conclusion, the present study indicates that low-pressure
implantation of 2.5-mm DES for very small vessels less than 2.5 mm
in diameter may  be feasible with regard to short- and long-term
clinical outcomes.
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